Local Therapies for the Global COVID-19 Pandemic
Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as…
Certara2020年5月29日
Data Validation in Clinical Research: Confusing Rules Explained
What should you do when faced with confusing findings during data validation in clinical research? …
Certara2020年4月30日
Applying decision analysis to drug development for COVID-19 & future pandemics
This blog discusses how decision analysis approaches can help drug developers to better decisions under…
Certara2020年4月30日
Getting started with in-house development: storyboarding
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020年2月21日
The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
Certara2020年2月19日
Getting started with in-house development: how does it work?
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020年2月10日
How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive…
Certara2020年1月24日
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Certara2020年1月17日
